Alaunos Therapeutics Inc. has announced early data from two non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN-1003, the company’s lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease (MASLD).